Sophia Abene

This week, the FDA set a target date for lenacapavir’s approval, as rising cases of dengue, measles, and other emerging threats continue to spread, alongside a dairy worker transmitting avian flu to his cats.

The fixed-dose combination will be used outside the EU to treat soil-transmitted helminths and lymphatic filariasis.

Jeff Freiberg, MD, PhD, on the rising emerging infection concerns of dengue, mpox, measles, and H5N1 influenza in clinical practice.

Andrew Engeli explains Ginkgo's role in the €24 million EU-Funded RANGER project for emerging infectious disease surveillance and response.

Sean Ong discusses how persistent fever beyond 72 hours emerges as a stronger predictor of mortality in MRSA bacteremia compared to CRP and WBC counts.

Oliver A Cornely shares guidance on tackling Candida infections in an evolving landscape, including rising resistance and taxonomic changes.

Elke Wollants explains how wastewater surveillance in Belgium provided an early warning for measles outbreaks, offering insights into broader virus circulation.

Confirmed measles cases in Texas have risen from 24 to 58 in just six days, with 13 hospitalizations reported.

Emily Ricotta, PhD, MSc outlines the importance of involving affected populations and refining data collection methods to improve early decision-making during epidemics

Koos Korsten, MD, PhD, MSc discusses how clinical context, including prevalence and outbreak situations, influences the choice between PCR and culture-based diagnostics for Candidozyma auris.

Emily Ricotta, PhD, MSc, discusses how observational studies shape early decisions and address challenges in infectious disease outbreaks

In the Phase 3 trial, GSK's vaccine met all 11 primary endpoints, providing expanded options for preventing invasive meningococcal disease in individuals aged 10-25 years.

Su H Wang, MD, FACP, MPH discusses combating vaccine misinformation, preventing outbreaks, and highlighting global health interconnectedness

Su H Wang, MD, FACP, MPH, cautions that the US withdrawal from the WHO and cuts to critical health programs may reverse progress in global health, with vulnerable populations being particularly at risk.

Kei Sato, PhD, provides insights into the factors driving the spread and immune resistance of the LP.8.1 SARS-CoV-2 variant across different countries.

Carlien Pohl-Albertyn's, PhD research highlights the role of the South African brown locust in the transmission and survival of the emerging pathogen Candida auris.

Hannah Pye, PhD and Evelien Adriaenssens, PhD explore the potential of phages in combating antimicrobial resistance and advancing health across human, animal, and environmental domains.

Professor Gordon Ramage, BSc, PhD, discusses the increasing impact of fungal biofilms, new treatment options, and the need for enhanced detection methods.

Heather Platt, MD, discusses Merck’s latest achievement with Capvaxive and its potential to significantly reduce invasive pneumococcal disease and pneumonia in high-risk adult populations across Europe.

FDA investigates ongoing outbreaks involving contaminated pastries with 18 reported cases of illness across 7 states, and 1 hospitalization.

Carole Mitnick, ScD discusses the impact of the endTB trial's findings on future TB treatment options, including shorter treatment durations, lower costs, and expanded accessibility.

Carole Mitnick, ScD highlights the importance of trust in the success of the endTB trial and addresses the ongoing toxicity concerns with new shorter treatment regimens.

Kirsten Nielsen, PhD, discusses how her team’s research could lead to better understanding and treatment of cryptococcal meningitis.

Researchers identify Camp Hill virus, a novel henipavirus in shrews, raising concerns about human exposure to emerging infectious diseases.

Robert Walker, MD discussed the company's application for full licensure and the importance of vaccination.

Fecal microbiota transplantation emerges as the top treatment, while probiotics show limited effectiveness in preventing CDI recurrence.

The latest Phase 2/3 trial results show NVX-CoV2601 outperforms its predecessor, offering protection against emerging COVID-19 strains.

European agencies warn that non-medical fungicide use may be fueling resistance in A fumigatus, a mold responsible for severe human infections.

Robert Allen, MD, on variant monitoring, antibody development, and the company's long-term approach to patient care.

Sasirekha Ramani, PhD on creating a broad-spectrum antiviral that could be effective in various clinical settings, especially given the emergence of new and more dominant strains.